What Wegovy dose works — and how does the schedule get you there?

Why doesn't Wegovy just start at the dose that works?

This is probably the most common question our prescribers hear. Semaglutide affects gut motility quite noticeably, nausea, loose stools, and burping are particularly common in the early weeks. Starting at 0.25 mg is not a therapeutic dose in the sense of producing significant weight loss; its job is to let your digestive system adjust before the dose climbs. Think of it as settling your system in, not treating your weight.

The standard UK pathway moves through 0.25 mg and 0.5 mg as starter doses, then 1.0 mg, 1.7 mg, and finally 2.4 mg, with roughly four weeks at each level. Your prescriber decides the pace. If side effects are difficult at a given step, the titration may pause there longer. Rushing the schedule is not something you can or should do alone; the NHS semaglutide guidance is clear that dose changes are made in discussion with a clinician, not by the patient independently.

Some people reach 2.4 mg and lose little after six months. The MHRA's 2026 approval of a 7.2 mg dose opens a further option for those patients, though eligibility is assessed by a prescriber, not self-selected. If you are curious about the full range of Wegovy doses and what each stage looks like in practice, that page covers the detail.

At which dose does Wegovy start producing noticeable weight loss?

Most people begin to notice appetite changes within the first few weeks, even at lower doses. Actual weight change, though, tends to become clearer once the maintenance dose is reached and held. The landmark STEP 1 trial, published in the New England Journal of Medicine, followed adults with obesity over 68 weeks on 2.4 mg semaglutide alongside lifestyle support. Average body-weight reduction was around 15%. That figure matters because it comes from a rigorous, placebo-controlled population, not a curated sample.

Weight loss is rarely linear. Many people describe a pattern of faster initial progress as appetite falls sharply, followed by a slower middle phase, and then a plateau. A plateau on maintenance dose does not always mean the medicine has stopped working; it can reflect a new energy equilibrium your body has found. If you want a clear breakdown of at what dose Wegovy actually works, that page gives an honest account of the evidence behind each step in the schedule. The question of when Wegovy starts working deserves its own honest answer, and that page goes into more depth on timelines.

Results vary between individuals based on starting weight, diet, activity, adherence, and other biological factors. Clinical trial averages describe a population, not a guarantee. Wegovy is not licensed or appropriate as a quick fix or for cosmetic weight loss, as the MHRA has stated explicitly.

What changes at 7.2 mg, and who is it for?

The 7.2 mg dose was initially approved in January 2026 as three 2.4 mg pens taken in a single weekly dose. On 14 April 2026 the MHRA approved a dedicated single-dose 7.2 mg pen, one pre-set weekly injection with a built-in covered needle that locks after use. Trial data reported average weight loss of around 20.7% over 72 weeks, narrowing the gap with tirzepatide's headline results considerably.

The 7.2 mg pen is licensed for adults with a BMI of 30 or above only. It is not approved for those with a BMI below 30, and it does not apply to the separate cardiovascular indication. The titration still begins at 0.25 mg; 7.2 mg is reached at the end of the schedule, not at the start. A prescriber assesses suitability, someone who has responded well at 2.4 mg may not need to go further, and the decision is clinical.

If you are thinking about how Wegovy's different strengths compare in terms of evidence and eligibility, that page pulls the threads together. For most people, the conversation about whether 7.2 mg is appropriate happens after a period of treatment, not at the outset.

How does a prescriber decide which dose is right for me?

A prescriber looks at several things at once: your starting BMI, your weight-related conditions, your current medicines, your response to any previous treatment, and how you are tolerating each dose step as you go through it. Wegovy is a Prescription-Only Medicine, and those decisions belong to the clinical consultation, not to a comparison table online.

At nume, sorry, at our pharmacy, a GPhC-registered Independent Prescriber reads your consultation personally, the same day you submit it. Before any prescription, we verify your identity with photo ID and confirm your weight on a short video call. Repeat orders are clinically re-reviewed each time; a dose increase requires evidence. None of that is bureaucratic delay, it is what keeps treatment safe. If you want to understand which Wegovy dosage tends to produce the best outcomes, that page covers the clinical picture in more depth.

If you are comparing Wegovy's dose trajectory with tirzepatide's, or thinking about cost alongside effectiveness, our Wegovy cost guide sets out what to expect from private prescription pricing honestly, including what a low price can sometimes signal. One practical note: prescribers are available Monday to Friday, and if your first consultation lands on a Friday before a bank holiday weekend, dispatch happens the next working day. Worth factoring that in if timing matters.

Ready to find out whether Wegovy is clinically appropriate for you? Start your free consultation and a prescriber will review your answers the same day.